NICE Recommends BeiGene's BRUKINSA (zanubrutinib) for Patients with Waldenström's Macroglobulinemia who have had at Least One Treatment
BRUKINSA Is the First Bruton's Tyrosine Kinase (BTK) Inhibitor Recommended by NICE for Routine Use for WM BRUKINSA Is the Only BTK Inhibitor Considered Cost Effective in WM BeiGene (NASDAQ: BGNE
Source: finanznachrichten.de